Novartis' Sandoz division announced plans to strengthen its European antibiotics manufacturing business by expanding production capabilities in Kundl, Austria and Palafolls, Spain.
In Kundl, Sandoz will invest more than $122 million (€100 million) to introduce new manufacturing technology for the production of oral amoxicillin, an API for its leading penicillin product. The investment will allow Sandoz to leverage its position in Kundl as the hub and center of the only major end-to-end antibiotics supply chain in Europe, covering all production steps from API to finished dosage forms for many leading antibiotics.
Sandoz will also expand its Palafolls site in Spain, investing around $61 million (€50 million) in new production technology and increased capacity for the production of sterile penicillin APIs and sterile API mixtures.
As part of this network modernization plan, Sandoz will phase out the current production of oral APIs at the Les Franqueses site in Spain, which it plans to close in 2024. Sterile API production is planned to transfer from Kundl to the new facility at Palafolls in 2025.
Read the press release
